Viridian Therapeutics (1S1) Price & Analysis

2 Followers

1S1 Stock Chart & Stats

€20.60

€0.10(0.60%)

At close: Jul 24 4:00 PM EDT

€20.60

€0.10(0.60%)

Day’s Range― - ―

52-Week Range€11.20 - €28.58

Previous CloseN/A

Volume0.00

Average Volume (3M)17.00

Market Cap

€2.21B

Enterprise Value€1.34K

Total Cash (Recent Filing)€981.53M

Total Debt (Recent Filing)€242.88M

Price to Earnings (P/E)―

Beta-0.03

Next Earnings

Nov 16, 2026

EPS Estimate

-0.85

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.53

Shares Outstanding113,292,270

10 Day Avg. Volume0

30 Day Avg. Volume17

Financial Highlights & Ratios

PEG Ratio0.57

Price to Book (P/B)3.65

Price to Sales (P/S)37.25

P/FCF Ratio-9.53

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€29.05

Price Target Upside41.01% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering13

EPS Forecast (FY)-3.29

Revenue Forecast (FY)€18.64M

Bulls Say, Bears Say

Bulls Say

Revenue ExpansionThe sharp revenue step-up indicates that Viridian has begun converting development activities into meaningful reported revenue. Although commercial maturity is not established, a larger revenue base can support partnerships, validate program value, and improve future financing and commercialization potential.

Balance Sheet FlexibilitySubstantial equity and low leverage provide Viridian with greater financial flexibility than a highly indebted development-stage biotech. This balance-sheet support can help fund clinical programs, absorb ongoing losses, and preserve strategic options while the pipeline advances toward potential approval.

Funding And Manufacturing ReadinessThe capital raise and completed debt repayment strengthen near-term funding flexibility, while the WuXi agreement supports manufacturing preparedness. Together, these actions improve execution capacity and reduce financing obligations as Viridian progresses its therapeutic programs toward potential commercialization.

Bears Say

Persistent Net LossesThe scale of ongoing losses shows that Viridian remains far from profitability despite higher revenue. Continued heavy operating expenses can erode equity, require additional financing, and limit the company’s ability to become self-sustaining before successful clinical and regulatory outcomes.

Substantial Cash BurnDeeply negative operating and free cash flow indicate that current activities consume substantial cash rather than funding themselves. This creates continuing dependence on external capital and makes future liquidity sensitive to clinical progress, financing access, and the timing of potential commercial revenue.

No Approved Commercial ProductWithout an approved product, Viridian lacks recurring commercial revenue to offset research and development spending. Future revenue depends on advancing its pipeline, obtaining regulatory approvals, and successfully commercializing therapies, leaving the business exposed to development and approval execution risk.

Viridian Therapeutics News

Viridian Therapeutics price target raised to $39 from $38 at Truist

Truist raised the firm’s price target on Viridian Therapeutics (VRDN) to $39 from $38 and keeps a Buy...

1M ago

VRDN

Viridian Therapeutics price target raised to $36 from $35 at RBC Capital

RBC Capital analyst Lisa Walter raised the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $35...

1M ago

VRDN

Joseph Thome Reiterates Buy on Viridian, Citing Strong Early Lumvoa Launch and Long-Term Growth from Elegrobart

TD Cowen analyst Joseph Thome has maintained their bullish stance on VRDN stock, giving a Buy rating yesterday....

1M ago

VRDN

Viridian: Buy Rating Reiterated as Lumvoa Launch Progress Supports Pipeline Outlook; $34 Price Target Unchanged

In a report released today, Serge Belanger from Needham maintained a Buy rating on Viridian Therapeutics, with a...

1M ago

VRDN

Viridian Therapeutics reports EPS ($1.05), consensus ($1.03)

Reports revenue $284,000 vs. $75,000 last year”We are very encouraged by the early indications from our recent launch...

1M ago

VRDN

Viridian Therapeutics sees cash runway through profitability

Cash, cash equivalents, and marketable securities were $981.5 million as of June 30, 2026, compared with $762.2 million...

1M ago

VRDN

“Stay Invested”: Wells Fargo Picks 2 Stocks to Buy as It Stays Bullish on the Market

What to make of the markets today? The biggest story in recent months has been the conflict in...

2M ago

AEIS

VRDN

Viridian Therapeutics price target raised to $43 from $32 at Wedbush

Wedbush analyst Laura Chico raised the firm’s price target on Viridian Therapeutics (VRDN) to $43 from $32 and...

3M ago

VRDN

Viridian Therapeutics price target raised to $38 from $35 at Truist

Truist raised the firm’s price target on Viridian Therapeutics (VRDN) to $38 from $35 and keeps a Buy...

3M ago

VRDN

Viridian Therapeutics price target raised to $35 from $34 at RBC Capital

RBC Capital raised the firm’s price target on Viridian Therapeutics (VRDN) to $35 from $34 and keeps an...

3M ago

VRDN

Viridian Therapeutics price target raised to $39 from $35 at Goldman Sachs

Goldman Sachs raised the firm’s price target on Viridian Therapeutics (VRDN) to $39 from $35 and keeps a...

3M ago

VRDN

Viridian Initiated at Buy as Lumivoa FDA Approval Transitions Company to Commercial Stage; $35 Price Target Reiterated

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Viridian Therapeutics, retaining the price target of...

3M ago

VRDN

Wells upgrades Viridian Therapeutics as Lumvoa launch KPIs likely to outperform

As previously reported, Wells Fargo analyst Derek Archila upgraded Viridian Therapeutics (VRDN) to Overweight from Equal Weight with...

3M ago

VRDN

Viridian Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo

Wells Fargo upgraded Viridian Therapeutics (VRDN) to Overweight from Equal Weight with a price target of $31, up...

3M ago

VRDN

1S1 FAQ

What was Viridian Therapeutics’s price range in the past 12 months?

Viridian Therapeutics lowest stock price was €11.20 and its highest was €28.58 in the past 12 months.

What is Viridian Therapeutics’s market cap?

Viridian Therapeutics’s market cap is €2.21B.

When is Viridian Therapeutics’s upcoming earnings report date?

Viridian Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 59 days.

How were Viridian Therapeutics’s earnings last quarter?

Viridian Therapeutics released its earnings results on Aug 06, 2026. The company reported -€0.908 earnings per share for the quarter, missing the consensus estimate of -€0.895 by -€0.013.

Is Viridian Therapeutics overvalued?

According to Wall Street analysts Viridian Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Viridian Therapeutics pay dividends?

Viridian Therapeutics does not currently pay dividends.

What is Viridian Therapeutics’s EPS estimate?

Viridian Therapeutics’s EPS estimate is -0.85.

How many shares outstanding does Viridian Therapeutics have?

Viridian Therapeutics has 113,292,270 shares outstanding.

What happened to Viridian Therapeutics’s price movement after its last earnings report?

Viridian Therapeutics reported an EPS of -€0.908 in its last earnings report, missing expectations of -€0.895. Following the earnings report the stock price went down -2.222%.

Which hedge fund is a major shareholder of Viridian Therapeutics?

Currently, no hedge funds are holding shares in DE:1S1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Viridian Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

88.42%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Viridian Therapeutics

Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.

Viridian Therapeutics (1S1) Earnings & Revenues

Historic Earnings Reports

1S1 Stock 12 Month Forecast

Average Price Target

€29.05

▲(41.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"€10","23":"€23","36":"€36","16.5":"€16.5","29.5":"€29.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35.55231811,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€35.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.048845285000006,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€29.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.07685362,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€19.08</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,16.5,23,29.5,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.8,21.011716777692307,22.223433555384617,23.435150333076923,24.646867110769232,25.85858388846154,27.070300666153848,28.282017443846154,29.49373422153846,30.70545099923077,31.91716777692308,33.12888455461538,34.34060133230769,{"y":35.55231811,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.8,20.51144963730769,21.222899274615386,21.934348911923077,22.645798549230772,23.357248186538463,24.068697823846158,24.78014746115385,25.491597098461543,26.203046735769234,26.91449637307693,27.62594601038462,28.33739564769231,{"y":29.048845285000006,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.8,19.744373355384617,19.68874671076923,19.633120066153847,19.577493421538463,19.521866776923076,19.466240132307693,19.41061348769231,19.354986843076926,19.29936019846154,19.243733553846155,19.188106909230772,19.132480264615385,{"y":19.07685362,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.455,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.995,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.24,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.68,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.36,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.36,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.47,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.485,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.1,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.3,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.8,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >